Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s.
In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2024 – it will be marketed as Accrufer®.
We also have an exclusive licence agreement with ASK Pharm, who will lead development and commercialisation in China.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @proactive_UK: $STX Shield Therapeutics looks forward to US launch of Accrufer after transformational year https://t.co/JK73DbuOln @shie…
RT @VOXmarkets: .@ShieldTx hails ‘transformational’ 2020 while it prepares for US launch of Accrufer®, @proactis said progress continues to…
RT @VOXmarkets: STX hails ‘transformational’ 2020 while it prepares for US launch of Accrufer® @ShieldTx https://t.co/fmnSY8DI8r #inves…
